RxDoctor Payments Data

Angela Soltero, APRN

Nurse Practitioner · Louisville, KYNPI 1366830044

Payments from drug & device makers

$3,176in general payments, 2019–2025

Across 126 payments — averaging $25.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$973
  • Regeneron Healthcare Solutions, Inc.$347
  • Amgen$333
  • Teva Pharmaceuticals USA, Inc.$222
  • GSK$154
  • Pharming Healthcare, Inc.$132
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,08097%
  • Education$963%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,176 in reported general payments places this provider in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$17,253
Medicare patients
85
Services billed
520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$36,075
Breo ElliptaFluticasone/Vilanterol43$19,638
Spiriva RespimatTiotropium Bromide25$13,903
SymbicortBudesonide/Formoterol Fumarate26$7,943
Advair HfaFluticasone Propion/Salmeterol13$7,935
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$7,695
DuleraMometasone/Formoterol16$5,443
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$3,483
Azelastine-FluticasoneAzelastine/Fluticasone24$2,867
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$2,584
Azelastine Hcl70$1,948
Albuterol Sulfate HfaAlbuterol Sulfate59$1,467
Montelukast Sodium126$1,169
Epinephrine11$1,088
Fluticasone Propionate72$1,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$154$55,71483 claims
AstraZenecaSymbicort, Breztri Aerosphere$973$15,63839 claims
Boehringer IngelheimSpiriva Respimat$83$13,90325 claims
Hikma Pharmaceuticals USAEpinephrine$18$1,08811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →